US2014141071A1PendingUtilityA1

Orally administrable liposomally encapsulated reduced glutathione, with n-o enhancing compounds for reversal and prevention of oxidation of cholesterol and of low density lipoprotein

Assignee: YOUR ENERGY SYSTEMS LLCPriority: Nov 7, 2004Filed: Jan 27, 2014Published: May 22, 2014
Est. expiryNov 7, 2024(expired)· nominal 20-yr term from priority
A61P 39/00A61P 3/06A61P 9/10A61P 37/02A61P 9/00A61P 3/10A61P 39/06A61P 25/16A61P 31/12A61K 38/063A61P 1/16A61K 31/366A61K 9/127A61K 38/05A61K 31/198A61K 33/04A61K 31/122A61K 38/00A61K 45/06A61K 9/4808
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.

Claims

exact text as granted — not AI-modified
1 - 22 . (canceled) 
     
     
         23 . A pharmaceutical composition for treatment of vascular disease, in a mammalian patient, comprising:
 reduced glutathione in a liposomal formulation capable of administration intravenously, orally, dermally or mucosally, where the concentration of reduced glutathione in the entrapped aqueous space of the liposomes is at least 123 mM; and   a compound selected from the group of materials that increase nitric oxide production.   
     
     
         24 . The pharmaceutical composition according to  claim 23 , further comprising:
 said compound selected from the group of materials that increase nitric oxide production being arginine.   
     
     
         25 . The pharmaceutical composition according to  claim 23 , further comprising:
 said compound selected from the group of materials that increase nitric oxide production being lysine.   
     
     
         26 . The pharmaceutical composition according to any one of  claims 23 - 25 , further comprising:
 selenium.

Join the waitlist — get patent alerts

Track US2014141071A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.